BioLineRx Ltd (BLRX) - Total Liabilities
Based on the latest financial reports, BioLineRx Ltd (BLRX) has total liabilities worth $17.56 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore BLRX net assets growth trend to track the company's year-over-year net asset growth rate.
BioLineRx Ltd - Total Liabilities Trend (2008–2025)
This chart illustrates how BioLineRx Ltd's total liabilities have evolved over time, based on quarterly financial data. See BioLineRx Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
BioLineRx Ltd Competitors by Total Liabilities
The table below lists competitors of BioLineRx Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TR Property Investment Trust plc
LSE:TRY
|
UK | GBX149.71 Million |
|
RE Royalties Ltd
V:RE
|
Canada | CA$45.99 Million |
|
Insimbi Refractory Alloy Supply
JSE:ISB
|
South Africa | ZAC817.19 Million |
|
Trimitra Propertindo Tbk PT
JK:LAND
|
Indonesia | Rp355.79 Billion |
|
Eurobattery Minerals AB
F:EBM
|
Germany | €40.81 Million |
|
Sheffield Resources Ltd
AU:SFX
|
Australia | AU$226.00K |
|
Praxis Home Retail Limited
NSE:PRAXIS
|
India | Rs2.60 Billion |
|
Golden Arrow Resources Corp
V:GRG
|
Canada | CA$890.79K |
Liability Composition Analysis (2008–2025)
This chart breaks down BioLineRx Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of BioLineRx Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioLineRx Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioLineRx Ltd (2008–2025)
The table below shows the annual total liabilities of BioLineRx Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $17.56 Million | -30.99% |
| 2024-12-31 | $25.45 Million | -49.81% |
| 2023-12-31 | $50.70 Million | +98.50% |
| 2022-12-31 | $25.54 Million | +91.99% |
| 2021-12-31 | $13.30 Million | -47.33% |
| 2020-12-31 | $25.26 Million | +25.13% |
| 2019-12-31 | $20.19 Million | +35.37% |
| 2018-12-31 | $14.91 Million | +84.46% |
| 2017-12-31 | $8.08 Million | +106.65% |
| 2016-12-31 | $3.91 Million | +5.96% |
| 2015-12-31 | $3.69 Million | -16.09% |
| 2014-12-31 | $4.40 Million | -46.76% |
| 2013-12-31 | $8.27 Million | -11.47% |
| 2012-12-31 | $9.34 Million | +37.18% |
| 2011-12-31 | $6.81 Million | +6.40% |
| 2010-12-31 | $6.40 Million | -41.23% |
| 2009-12-31 | $10.88 Million | +10.09% |
| 2008-12-31 | $9.89 Million | -- |
About BioLineRx Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the tr… Read more